查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1967686

查核点抑制剂抗药性癌症市场－全球产业规模、份额、趋势、机会、预测：按类型、应用、地区和竞争格局划分，2021-2031年

Checkpoint Inhibitor Refractory Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球查核点抑制剂抗药性癌症市场预计将从 2025 年的 352.5 亿美元成长到 2031 年的 574.8 亿美元，复合年增长率为 8.49%。

该市场涵盖用于治疗经免疫查核点抑制剂初始治疗后復发或进展的恶性肿瘤的疗法。该领域的根本驱动力在于免疫疗法越来越多地被纳入一线治疗标准，从而导致符合挽救性治疗条件的患者数量不断增加。美国癌症协会 (ACS) 估计，到 2024 年，美国将新增 2,001,140 例癌症病例，这凸显了庞大的患者群体将推动对持续治疗方案的需求。

市场概览
预测期 2027-2031
市场规模：2025年 352.5亿美元
市场规模：2031年 574.8亿美元
复合年增长率：2026-2031年 8.49%
成长最快的细分市场 PD-1抑制剂
最大的市场 北美洲

然而，该行业面临着与疾病进展的复杂生物学特征相关的重大挑战。阻碍市场成长的主要障碍是肿瘤微环境中观察到的抗药性机制的高度多样性。这种异质性使得药物研发人员难以识别通用生物标记并开发有效的联合通讯协定。

市场驱动因素

市场成长的主要驱动力是患者群体不断扩大，而这又得益于第一线免疫疗法的日益普及。随着免疫查核点抑制剂成为多种恶性肿瘤早期阶段的标准治疗方案，接受此类治疗期间或治疗后病情进展的患者数量将会增加，从而形成一个需要补救治疗的特殊患者群体。这迫使研发公司优先开发能够克服获得性抗药性的药物。例如，默克公司于2024年4月发布的2024年第一季季财报显示，Keytruda的全球销售额达到69亿美元，年增20%，显示一线疗法的广泛应用将为后续治疗提供大量潜在候选患者。

同时，战略联盟的激增和对下一代免疫肿瘤学研究的资金筹措，正推动着一系列联合治疗的蓬勃发展。研发人员正积极收购T细胞衔接器和抗体药物复合体（ADC）等资产，以绕过抑制早期查核点抑制剂的肿瘤微环境。默克公司于2024年1月宣布以约6.8亿美元收购Harporn Therapeutics，旨在推进其针对免疫疗法抗药性固态肿瘤的T细胞衔接器产品组合，这便是这一趋势的一个典型例证。这项投资活动与新治疗方法临床疗效的持续验证一致。例如，Iovance BioTherapeutics在2024年2月发布的新闻稿中指出，其细胞疗法Amtagvi在先前接受过PD-1抑制剂抗体治疗的转移性黑色素瘤患者中取得了31.5%的客观缓解率。

市场挑战

肿瘤微环境中抗药性机制的巨大多样性对全球查核点抑制剂抗药性癌症市场的成长构成了重大障碍。这种生物异质性使药物研发过程复杂化，这意味着对一位患者有效的治疗通讯协定往往由于免疫逃脱途径的差异而对另一位患者无效。因此，研究人员难以检验能够可靠预测患者对挽救性治疗反应的通用生物标记物，迫使研发人员进行更大规模、高成本、耗时更长的临床试验来证明统计学意义，这常常导致监管核准和产品上市延迟。

此外，难以对抗药性类型进行分类限制了新药的目标患者群体，并限制了新兴疗法的推广应用。根据癌症研究所 (CRI) 2024 年的报告，约 45% 的新确诊癌症患者可能适合接受免疫疗法，但肿瘤抗药性的复杂性仍然使绝大多数患者无法获得有效的治疗方案。这项限制阻碍了市场收入潜力，因为如果没有精准且统一的生物标的支持，企业很难将治疗方法推广到更广泛的难治性患者群体。

市场趋势

个人化mRNA新抗原疫苗联合治疗的进展正逐渐成为恢復抗药性恶性肿瘤免疫辨识的关键策略。与标准免疫疗法不同，这些疫苗根据患者的肿瘤特征编码特定的新抗原，激活T细胞攻击那些已逃避常规抑制的细胞。随着研发人员与PD-1抑制剂合作以提高疫苗的持久性，这种方法正获得越来越多的关注。根据默克公司2024年6月发布的新闻稿，数据显示，在III/IV期高风险黑色素瘤患者中，与Pembrolizumab单药治疗相比，mRNA-4157 (V940) 与Keytruda联合治疗可将復发或死亡风险降低49%。

同时，将抗体药物复合体（ADC）策略性地纳入免疫疗法后的治疗方法，正在重塑查核点抑制剂治疗后晚期癌症患者的治疗模式。 ADC 透过将细胞毒性药物直接递送至表达抗原的癌细胞，提供了一种绕过导致查核点抗药性的免疫抑制微环境的机制，使其成为对持续免疫治疗无反应的固体癌的首选挽救疗法。吉利德科学公司在 2024 年 8 月发布的第二季财报中宣布，其 ADC 药物 Trodervi 的销售额成长了 23%，达到 3.2 亿美元，这标誌着这一转变的到来。此成长主要得益于转移性三阴性乳癌二线治疗领域的需求，许多患者在用尽初始免疫治疗方案后需要有效的治疗。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球查核点抑制剂癌症市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 按类型（PD-1抑制剂、PD-L1抑制剂、其他）
    • 适用疾病（肺癌、膀胱癌、恶性黑色素瘤、何杰金氏淋巴瘤等）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美抗癌药物查核点抑制剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲查核点抑制剂抗药性癌症市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区抗癌药物查核点抑制剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲地区查核点的市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲查核点抑制剂抗药性癌症市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球查核点抑制剂抗药性癌症市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Bristol-Myers Squibb Company.
  • AstraZeneca plc.
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals Inc
  • Pfizer Inc
  • Janssen Global Services, LLC
  • 4SC AG
  • Mirati Therapeutics, Inc.
  • Ascentage Pharma

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 20171

The Global Checkpoint Inhibitor Refractory Cancer Market is projected to expand from USD 35.25 billion in 2025 to USD 57.48 billion by 2031, registering a CAGR of 8.49%. This market comprises therapeutic agents designed to treat malignancies that relapse or progress following initial treatment with immune checkpoint blockades. The sector is fundamentally driven by the rising integration of immunotherapies into first-line standards of care, which subsequently increases the population of patients eligible for salvage treatments. According to the American Cancer Society, the projection of 2,001,140 new cancer cases in the United States in 2024 highlights the substantial patient base fueling the demand for consecutive therapy lines.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 35.25 Billion
Market Size 2031USD 57.48 Billion
CAGR 2026-20318.49%
Fastest Growing SegmentPD-1 inhibitor
Largest MarketNorth America

However, the industry faces significant hurdles related to the complex biology of disease progression. A major obstacle impeding market growth is the high variability of resistance mechanisms found within the tumor microenvironment. This heterogeneity complicates the ability of pharmaceutical developers to identify universal biomarkers and create effective combination protocols.

Market Driver

A primary accelerator for the market is the expansion of the addressable patient pool resulting from increased frontline immunotherapy adoption. As immune checkpoint inhibitors become the standard of care for earlier stages of various malignancies, the number of patients eventually progressing on or after these therapies rises, creating a distinct population in need of salvage interventions and compelling developers to prioritize agents that overcome acquired resistance. For instance, Merck's 'First Quarter 2024 Financial Results' in April 2024 reported a 20% increase in worldwide Keytruda sales to $6.9 billion, illustrating the massive scale of frontline adoption that feeds the pipeline of patients potentially eligible for subsequent lines of therapy.

Simultaneously, a surge in strategic alliances and funding for next-generation immuno-oncology research is driving a robust pipeline of combination therapies. Developers are actively acquiring assets such as T-cell engagers and antibody-drug conjugates to bypass the immunosuppressive tumor microenvironment that renders initial checkpoint blockade ineffective. Exemplifying this trend, Merck announced in January 2024 that it invested approximately $680 million to acquire Harpoon Therapeutics to advance a portfolio of T-cell engagers targeting immunotherapy-resistant solid tumors. This investment activity aligns with continued clinical validation of new modalities, as evidenced by Iovance Biotherapeutics' February 2024 press release stating that the cell therapy Amtagvi achieved an objective response rate of 31.5% in metastatic melanoma patients previously treated with a PD-1 blocking antibody.

Market Challenge

The extensive variability of resistance mechanisms within the tumor microenvironment presents a formidable barrier to the growth of the Global Checkpoint Inhibitor Refractory Cancer Market. This biological heterogeneity implies that a treatment protocol effective for one patient often fails in another due to differing immune evasion pathways, thereby complicating the pharmaceutical development process. Consequently, researchers struggle to validate universal biomarkers that can reliably predict patient response to salvage therapies, forcing developers to conduct larger, costlier, and longer clinical trials to prove statistical significance, which frequently delays regulatory approvals and commercial product launches.

Furthermore, the inability to easily categorize resistance types restricts the addressable patient pool for new agents and limits the scalability of emerging drugs. According to the Cancer Research Institute in 2024, while approximately 45 percent of newly diagnosed cancer patients were eligible for immunotherapy, the intricate nature of tumor resistance continues to exclude the majority from effective treatment options. This limitation hampers market revenue potential, as companies cannot readily scale therapies across broader refractory populations without the aid of precise, unified biological targets.

Market Trends

The advancement of personalized mRNA neoantigen vaccines in combination settings is emerging as a critical strategy to restore immune recognition in resistant malignancies. Unlike standard immunotherapies, these vaccines encode specific neoantigens from a patient's tumor profile, priming T-cells to attack cells that have evaded prior blockade, an approach gaining momentum as developers pair vaccines with PD-1 inhibitors to enhance durability. According to a Merck press release in June 2024, data showed that the combination of mRNA-4157 (V940) and Keytruda reduced the risk of recurrence or death by 49% compared to pembrolizumab alone in patients with high-risk stage III/IV melanoma.

Concurrently, the strategic integration of Antibody-Drug Conjugates (ADCs) into post-immunotherapy regimens is reshaping the landscape for patients progressing after checkpoint inhibition. By delivering cytotoxic payloads directly to antigen-expressing tumor cells, ADCs provide a mechanism to bypass the immunosuppressive microenvironment responsible for checkpoint resistance, making them a preferred salvage therapy in solid tumors where continued immunotherapy is ineffective. Highlighting this shift, Gilead Sciences reported in its 'Second Quarter 2024 Financial Results' in August 2024 that sales of the ADC Trodelvy rose 23% to $320 million, primarily driven by demand in second-line metastatic triple-negative breast cancer where patients frequently require effective interventions after exhausting initial immune-based options.

Key Market Players

  • Bristol-Myers Squibb Company.
  • AstraZeneca plc.
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals Inc
  • Pfizer Inc
  • Janssen Global Services, LLC
  • 4SC AG
  • Mirati Therapeutics, Inc.
  • Ascentage Pharma

Report Scope

In this report, the Global Checkpoint Inhibitor Refractory Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Checkpoint Inhibitor Refractory Cancer Market, By Type

  • PD-1 Inhibitor
  • PD-L1 Inhibitor
  • Others

Checkpoint Inhibitor Refractory Cancer Market, By Application

  • Lung Cancer
  • Bladder Cancer
  • Melanoma
  • Hodgkin Lymphoma
  • Others

Checkpoint Inhibitor Refractory Cancer Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Checkpoint Inhibitor Refractory Cancer Market.

Available Customizations:

Global Checkpoint Inhibitor Refractory Cancer Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Checkpoint Inhibitor Refractory Cancer Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (PD-1 Inhibitor, PD-L1 Inhibitor, Others)
    • 5.2.2. By Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Checkpoint Inhibitor Refractory Cancer Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application

7. Europe Checkpoint Inhibitor Refractory Cancer Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. France Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America Checkpoint Inhibitor Refractory Cancer Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Checkpoint Inhibitor Refractory Cancer Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Checkpoint Inhibitor Refractory Cancer Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bristol-Myers Squibb Company.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. AstraZeneca plc.
  • 15.3. Merck KGaA
  • 15.4. F. Hoffmann-La Roche Ltd
  • 15.5. Regeneron Pharmaceuticals Inc
  • 15.6. Pfizer Inc
  • 15.7. Janssen Global Services, LLC
  • 15.8. 4SC AG
  • 15.9. Mirati Therapeutics, Inc.
  • 15.10. Ascentage Pharma

16. Strategic Recommendations

17. About Us & Disclaimer